Intensity-modulated reirradiation therapy (IMRT reirradiation)
Overview
Intensity-modulated reirradiation therapy (IMRT reirradiation) is the application of intensity-modulated radiation therapy — which uses computer-controlled linear accelerators to deliver precise radiation doses conformally shaped to the tumor volume while sparing adjacent normal tissues — to patients who have previously received radiotherapy to an overlapping field. In head and neck squamous cell carcinoma (HNSCC), reirradiation presents unique challenges due to cumulative dose to critical structures (spinal cord, salivary glands, mandible). IMRT techniques allow dose escalation to the recurrent tumor while minimizing re-irradiation of organs-at-risk.
Used by
- PMID:38780927 — IMRT-based reirradiation (concurrent and maintenance nivolumab) delivered in a multicenter, single-arm, nonrandomized phase 2 trial (NCT03521570) to 51 evaluable patients with locoregionally recurrent or second primary HNSCC in a previously irradiated field (≥40 Gy to >50% of target volume, ≥6 months prior); RPA classes 1–2 (MIRI criteria). Estimated 1-year PFS 61.7% (95% CI 49.2%–77.4%); primary endpoint met (P = .002 vs historical 43.8%). Grade ≥3 treatment-related AEs in 11.8%; no grade 5 events PMID:38780927.
Notes
- The MIRI Recursive Partitioning Analysis (RPA) classes 1–2 were used as eligibility and stratification criteria; class 3 was excluded PMID:38780927.
- QOL measured by FACT-G and FACT-H&N remained stable across 104 weeks, suggesting acceptable patient-reported tolerability for IMRT reirradiation combined with PD-1 blockade PMID:38780927.
- Corpus-grown slug; not present in canonical ontology.
Sources
This page was processed by crosslinker on 2026-05-04.